Interventional pulmonary procedures and their outcomes in patients with STAT3 hyper IgE syndrome.

Bronchopleural fistula Complications Dominant-negative STAT3 mutation Hyper-IgE syndrome Job’s syndrome Lung surgery

Journal

BMC surgery
ISSN: 1471-2482
Titre abrégé: BMC Surg
Pays: England
ID NLM: 100968567

Informations de publication

Date de publication:
23 Sep 2023
Historique:
received: 23 10 2022
accepted: 11 09 2023
medline: 25 9 2023
pubmed: 24 9 2023
entrez: 23 9 2023
Statut: epublish

Résumé

STAT3 hyperimmunoglobulin E syndrome (STAT3-HIES) also referred to as autosomal dominant HIES (AD-HIES) is an inborn error of immunity characterized by the classic triad of eczema, frequent opportunistic infections, and elevated serum IgE levels. As a consequence of lung sequels due to repeated infections and impaired tissue healing, patients may require interventional pulmonary procedures. Four patients with dominant-negative STAT3 mutations who had received interventional pulmonary procedures were enrolled. The demographic, clinical, and molecular characteristics were gathered through a medical record search. All reported STAT3-HIES patients in the literature requiring pulmonary procedures as part of their treatment were reviewed. Recurrent episodes of pneumonia and lung abscess were the most prevalent symptoms. The most common non-immunological features were scoliosis, failure to thrive, and dental problems such as primary teeth retention and disseminated decays. Bronchiectasis, lung abscess, pneumatocele, and cavitary lesion were the most prevalent finding on high-resolution computed tomography at the earliest recording. All patients underwent pulmonary surgery and two of them experienced complications. Patients with STAT3-HIES have marked pulmonary infection susceptibility which may necessitate thoracic surgeries. Since surgical procedures involve a high risk of complication, surgical options are recommended to be utilized only in cases of drug resistance or emergencies.

Sections du résumé

BACKGROUND BACKGROUND
STAT3 hyperimmunoglobulin E syndrome (STAT3-HIES) also referred to as autosomal dominant HIES (AD-HIES) is an inborn error of immunity characterized by the classic triad of eczema, frequent opportunistic infections, and elevated serum IgE levels. As a consequence of lung sequels due to repeated infections and impaired tissue healing, patients may require interventional pulmonary procedures.
METHOD METHODS
Four patients with dominant-negative STAT3 mutations who had received interventional pulmonary procedures were enrolled. The demographic, clinical, and molecular characteristics were gathered through a medical record search. All reported STAT3-HIES patients in the literature requiring pulmonary procedures as part of their treatment were reviewed.
RESULT RESULTS
Recurrent episodes of pneumonia and lung abscess were the most prevalent symptoms. The most common non-immunological features were scoliosis, failure to thrive, and dental problems such as primary teeth retention and disseminated decays. Bronchiectasis, lung abscess, pneumatocele, and cavitary lesion were the most prevalent finding on high-resolution computed tomography at the earliest recording. All patients underwent pulmonary surgery and two of them experienced complications.
CONCLUSION CONCLUSIONS
Patients with STAT3-HIES have marked pulmonary infection susceptibility which may necessitate thoracic surgeries. Since surgical procedures involve a high risk of complication, surgical options are recommended to be utilized only in cases of drug resistance or emergencies.

Identifiants

pubmed: 37741967
doi: 10.1186/s12893-023-02193-2
pii: 10.1186/s12893-023-02193-2
pmc: PMC10517538
doi:

Substances chimiques

STAT3 protein, human 0
STAT3 Transcription Factor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

289

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Chest. 2021 Apr;159(4):e181-e184
pubmed: 34022014
Am J Hum Genet. 1999 Sep;65(3):735-44
pubmed: 10441580
J Clin Immunol. 2021 Jul;41(5):934-943
pubmed: 33523338
J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):996-1001
pubmed: 28939137
Allergy. 2019 Sep;74(9):1691-1702
pubmed: 30793327
J Gastrointest Surg. 2013 May;17(5):1009-14
pubmed: 23188219
J Clin Immunol. 2013 Jul;33(5):896-902
pubmed: 23584561
Ann Allergy Asthma Immunol. 2013 Mar;110(3):204-5
pubmed: 23548533
Lancet. 1966 May 7;1(7445):1013-5
pubmed: 4161105
Nature. 2008 Apr 10;452(7188):773-6
pubmed: 18337720
Clin Mol Allergy. 2011 Nov 29;9:14
pubmed: 22126402
Respir Med Case Rep. 2020 Jun 12;30:101125
pubmed: 32577366
J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1986-1995.e3
pubmed: 30878710
J Clin Immunol. 2021 Jul;41(5):864-880
pubmed: 33932191
J Med Microbiol. 2020 Jun;69(6):844-849
pubmed: 32459615
N Engl J Med. 2007 Oct 18;357(16):1667-8
pubmed: 17942886
Clin Chest Med. 2016 Sep;37(3):557-67
pubmed: 27514600
Nature. 2007 Aug 30;448(7157):1058-62
pubmed: 17676033
J Clin Immunol. 2021 Nov;41(8):1804-1838
pubmed: 34390440
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620929225
pubmed: 32482141
JAKSTAT. 2013 Apr 1;2(2):e23435
pubmed: 24058807
J Int Med Res. 2021 Apr;49(4):3000605211008073
pubmed: 33900869
Curr Allergy Asthma Rep. 2020 Aug 24;20(11):65
pubmed: 32830295
N Engl J Med. 2007 Oct 18;357(16):1608-19
pubmed: 17881745
Scand J Immunol. 2013 Sep;78(3):258-65
pubmed: 23659370
CEN Case Rep. 2016 May;5(1):61-66
pubmed: 28509165
Medicine (Baltimore). 2018 Apr;97(14):e0215
pubmed: 29620631
Eur J Pediatr. 2011 May;170(5):661-6
pubmed: 21107604
J Am Acad Dermatol. 2011 Dec;65(6):1167-72
pubmed: 21703716
J Allergy Clin Immunol Pract. 2016 Nov - Dec;4(6):1054-1058
pubmed: 27693026
Pediatr Allergy Immunol Pulmonol. 2021 Mar;34(1):33-37
pubmed: 33734873
Case Reports Immunol. 2020 Dec 2;2020:6694957
pubmed: 33343952
J Clin Immunol. 2022 Oct;42(7):1473-1507
pubmed: 35748970
Immunol Cell Biol. 2019 Apr;97(4):368-379
pubmed: 30264496
Clin Dev Immunol. 2010;2010:289873
pubmed: 20490271
Immunol Allergy Clin North Am. 2019 Feb;39(1):49-61
pubmed: 30466772
J Pediatric Infect Dis Soc. 2014 Jun;3(2):e20-3
pubmed: 26625374
Ann N Y Acad Sci. 2012 Feb;1250:25-32
pubmed: 22268731

Auteurs

Seyed Alireza Mahdaviani (SA)

Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Soodeh Ghadimi (S)

School of Medicine, Islamic Azad University of Medical Sciences, Tehran, Iran. gh.soode@yahoo.com.

Mazdak Fallahi (M)

Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Seyedeh Atefeh Hashemi-Moghaddam (SA)

Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Zahra Chavoshzadeh (Z)

Immunology and Allergy Department, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Anne Puel (A)

Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France.

Nima Rezaei (N)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

Mahsa Rekabi (M)

Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Zahra Daneshmandi (Z)

Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Kambiz Sheikhy (K)

Lung Transplantation Research Center (LTRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abolghasem Daneshvar Kakhki (AD)

Lung Transplantation Research Center (LTRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Seyed Reza Saghebi (SR)

Tracheal Diseases Research Center (TDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Saviz Pejhan (S)

Tracheal Diseases Research Center (TDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Mahnaz Jamee (M)

Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. m.jamee@lumc.nl.
Pediatric Infections Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran. m.jamee@lumc.nl.
Laboratory for Pediatric Immunology, Department of Pediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, Netherlands. m.jamee@lumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH